MHAA4549A is a human IgG1 monoclonal antibody developed to treat influenza A infection. It targets a conserved epitope on the hemagglutinin stalk of the virus, neutralizing a wide range of influenza A strains. It has been tested in both healthy volunteers and hospitalized patients and was shown to be safe, with predictable pharmacokinetics similar to other IgG1 antibodies.
References
Deng, R., Lee, A.P., Maia, M. et al. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial. Clin Pharmacokinet 57, 367–377 (2018). https://doi.org/10.1007/s40262-017-0564-y
Generated at 2025-07-21T18:21:10Z
by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos
.Pharmacolibrary.Drugs.Z_Unclassified.J06B_ProbableImmunoglobulins.MHAA459A.MHAA459A_2C